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angiogenic factors in serum after thermoablation
of colorectal liver metastases
Marieke WJLAE Wertenbroek1, Marianne Schepers3, Hannetta J Kamminga-Rasker2, Jan T Bottema1,
Anneke C Muller Kobold2, Han Roelofsen3 and Koert P de Jong1*Abstract
Background: Thermoablation is used to treat patients with unresectable colorectal liver metastases (CRLM). We
analyze clinical outcome, proteome kinetics and angiogenic markers in patients treated by cryosurgical ablation
(CSA) or radiofrequency ablation (RFA).
Methods: 205 patients underwent CSA (n = 20), RFA (n = 22), partial hepatectomy (PH, n = 134) or were found truly
unresectable (n = 29). Clinical outcome, proteome transitions and angiogenic response in serum were analyzed at
various time points after ablation.
Result: Median overall survival in CSA patients (17.6 months) was worse (p < 0.0001) when compared to RFA
treated patients (51.7 months) and patients after PH (43.4 months). The complication rate was higher in the CSA
group (50%) as compared to the RFA group (22%). Proteomics analyses showed consistently more changes in
serum protein abundance with CSA compared to RFA. In the first four days after ablation a pro-angiogenic serum
response occurred.
Conclusions: RFA of CRLM is superior to CSA with a median survival which equals survival in patients after PH.
Proteomics analyses suggests a more aggravated serum response to CSA compared to RFA. Thermoablation is
associated with changes in serum levels of angiogenic factors favouring a pro-angiogenic environment, but without
differences between RFA and CSA.
Keywords: Thermoablation, Proteomics, Angiogenesis, Liver tumor, Partial hepatectomyBackground
Partial hepatectomy (PH) is a potential curative treatment
for patients with colorectal liver metastases (CRLM). Un-
fortunately, the majority of patients are not amenable for
PH because of bilobar metastases, widespread liver in-
volvement or insufficient liver remnant. The poor progno-
sis of patients with unresectable CRLM resulted in the
application of thermoablation either by cryosurgical abla-
tion (CSA) or radiofrequency ablation (RFA). Although
RFA seems to be the more widely applied technique, CSA
is still in use in patients with CRLM or hepatocellular* Correspondence: k.p.de.jong@umcg.nl
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distribution, and reproduction in any mediumcarcinoma (HCC) [1-6]. Since 2008, at least 12 original re-
ports on 546 patients with liver tumors treated with CSA
were published, of which 3 described more than 300 pa-
tients [6-8]. Contributing to the popularity of CSA might
be the claimed anti-cancer immune response associated
with cryoablation [9]. The results of RFA treatment for
CRLM revealed 5-year survival rates of 14-55%, ablation site
recurrence rates from 3.6 to 60%, and low major complica-
tion and mortality rates, 6-9% and < 2% respectively [10].
The question arises how these two ablation techniques
compare to each other. In general one can conclude
from the literature that the complication rate of CSA is
higher than RFA [11,12]. This seems to be related to the
systemic inflammatory response which is associated with
CSA [13-15]. Several lines of evidence relate inflamma-
tion to the development and progression of cancer;entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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nominator for both conditions [16-18]. Especially
angiopoietin-2 plays a dominant role not only in angio-
genesis, but also in initiation and maintenance of inflam-
mation [19-21]. A recent review summarized the
relation between inflammation, angiogenesis and tumor
progression and the possible impact that RFA of liver tu-
mors could have [22].
The aim of the present study is to compare CSA versus
RFA in patients with unresectable CRLM with respect to
clinical outcome. Furthermore we wanted to evaluate the
biochemical response and the temporal response in serum
protein expression in both ablation groups. Finally we
more specifically analyzed changes in the response of pro-
angiogenic and anti-angiogenic growth factors in serum.
We wanted to test the hypothesis that (1) CSA is associ-
ated with a more pronounced overall reaction with respect
to protein kinetics and (2) CSA is associated with a more
pronounced pro-angiogenic response as compared to
RFA. To test these hypotheses we performed (1) a com-
prehensive approach to analyze the dynamics of the serum
proteome and (2) analyzed changes in pro-angiogenic and
anti-angiogenic serum molecules induced by CSA versus
RFA in a subset of highly comparable patients in whom
only ablation was performed and in whom no post abla-
tion complications occurred.
Methods
Patient selection and treatment
The study is in compliance with the Declaration of
Helsinki (Sixth Revision, 2008). The study fulfils all the
requirements for patient anonymity and is in agreement
with regulations of the Medical Ethics Committee of the
University Medical Center Groningen for publication of
patient data.
We used our prospectively maintained liver surgery data-
base to identify all consecutive patients with CRLM who
underwent a laparotomy with the intention to perform a
PH alone or in combination with an ablation procedure.
All patients underwent intentionally curative resections of
the primary tumor, either previously or simultaneous with
the liver procedure.
Patient treatment is according to a standard protocol,
including CT-scan of thorax and abdomen, colonoscopy
and CEA-serum level. If the CRLM were judged treat-
able by either PH or ablation or a combination of both,
a laparotomy was performed. Ablation was performed if
a PH alone was not able to render the liver tumor-free,
except in 2 procedures in which comorbidity was the
reason that ablation was conducted because these patients
were not fit for PH. Suspicious lesions found during oper-
ation were sent for frozen section. Intraoperative liver
ultrasound was done to rule out hitherto undetected
CRLM. If the CRLM were judged resectable surgicaltreatment followed. If this situation could not be reached
by PH and/ or ablation, the patients were defined as truly
unresectable and included in the control (laparotomy only)
group. The type of treatment was discussed in a multidis-
ciplinary setting. No adjuvant chemotherapy was given
postoperatively. Patients judged to be truly unresectable
were offered the possibility of palliative chemotherapy. The
Fong clinical risk score (CRS) was calculated [23].
Equipment used for tumor ablation
Ablation was performed under intra-operative ultra-
sound guidance according to the manufacturers’ proto-
col. Cryoablation was performed under using the Cryo 6
equipment (Erbokryo-CS6 equipment, ERBE, Tübingen,
Germany). The RF 3000 TM Radio Frequency Ablation
System (Boston Scientific, Boston, MA, USA) was used
for RFA.
Follow-up of patients
All patients had the potential of at least 5 years of
follow-up. Mortality was defined as any death during
hospitalization or within 30 days from surgery. Follow-
up was performed every 3 months during the first two
years and every 6 months thereafter and included serum
CEA, liver ultrasound and thoracic X-ray in patients
after PH. Suspicious lesions were confirmed by CT scan
or magnetic resonance imaging (MRI) in case of contrast
allergy. Because CT scanning of ablated tumors is the
preferred imaging modality, CT (or MRI) replaced ultra-
sound in patients treated with ablation [24]. Recurrences
were treated by resection or ablation if limited or with
chemotherapy if local treatment was not intentionally
curative.
Biochemical and angiogenic growth factor serum
response after CSA or RFA
We selected 12 patients (n = 6 CSA, n = 6 RFA) with
comparable clinicopathological characteristics who
underwent ablation as a sole treatment –without con-
comitant PH- and who had an uncomplicated postoper-
ative course. These patients were used for comparison of
the response of relevant serum markers, serum protein
expression and angiogenic growth factors during the first
4 days after operation. None of these patients received
any transfusions of blood or thrombocytes or plasma
products. Routine blood tests are performed in all pa-
tients admitted for liver surgery and serum samples were
obtained by venipuncture at the day of admission to the
hospital (−1) at the end of surgery (day 0, only proteo-
mics and angiogenic growth factors) and at days 1, 2, 3
and 4. We considered the following markers relevant;
CRP and albumin as markers of the acute phase re-
sponse, LDH and ALAT to quantify liver tissue damage,
thrombocytes as a reservoir of angiogenesis-related
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anticoagulant, anti-inflammatory and anti-angiogenic
capacity. The following angiogenic molecules were de-
termined: vascular endothelial growth factor (VEGF),
hepatocyte growth factor (HGF), angiopoietin-2 (Ang-2),
human Tie-2 (all Quantikine ELISA kits, R&D Systems,
Minneapolis, USA). The anti-angiogenic molecules
angiopoietin-1 (Ang-1), endostatin (both Quantikine
ELISA kits) and angiostatin (RayBiotech Inc, Norcross,
USA) were determined. Values were expressed as a per-
centage change of the patients’ growth factor concentra-
tions at the day of admission (day −1).
SELDI-TOF-MS analysis
Monitoring the time-dependent protein expression dy-
namics that take place during disease progression, recov-
ery from surgery or in response to treatment or diet may
help to understand the underlying physiological and bio-
chemical processes as we have previously shown [25].
SELDI-TOF-MS is a high-throughput proteomics tech-
nology that allows rapid acquisition of protein expres-
sion profiles however it does not allow identification of
individual proteins but can show biological processes
that involve changes in serum protein abundance. Serum
samples were processed as described previously [25].
Briefly, samples were denatured by mixing 600 μl sample
with 400 μl 20% v/v acetronitril. Half of the denatured
sample was used directly for SELDI measurement
with sinapinic acid (SPA) as matrix. The other 500 μl
was used to prepare a low molecular weight fraction
using an ultra-filtration step with a 50 kDa cut-off and
was measured with α-cyano-4-hydroxycinnamic acid
(CHCA) as matrix. Samples were randomly applied in
triplicate to CM10 ProteinChip arrays and measured in
a ProteinChip system 4000 mass spectrometer (both
from Bio-Rad, Hercules CA, USA). Ciphergen Express
software 3.0 was used for data analyses with default
settings for baseline removal and normalization for total
ion current. Peaks that had a signal to noise ratio ≥ 5 in
at least 3 spectra were clustered (mass deviation ≤ 0.3%).
In the final dataset peaks detected with CHCA, in
the mass ranges 1–6.5 kDa and 6.5-30 kDa, were com-
bined with peaks detected with SPA, in the mass range
2–100 kDa.
Statistics
Continuous variables are presented as median and inter-
quartile range (IQR). Survival after surgery was calculated
from the day of surgery until the last follow-up date (May
2011) or until the day of death using the Kaplan-Meier
method with the log-rank test for comparison. Because pa-
tient inclusion stopped at May 2006, all patients had the
potential of at least 5 years of follow-up and therefore ac-
tual survival data are presented. None of the includedpatients were lost to follow-up except for deceased pa-
tients. Factors associated with overall and disease-free sur-
vival were examined using univariate and multivariate Cox
regression analysis. Chi square test was used for compari-
son of categorical variables. The serum response was com-
pared using baseline (day −1) values, and by measuring the
total response as area under the curve (AUC) from time
point 0 (day of operation) to day 4. Comparisons were
done using the Mann–Whitney U test. All p-values were
derived from two-tailed tests and were considered signifi-
cant if < 0.05.
Results
Clinical outcome of all patients
Patient and tumor characteristics in the four patient groups
In total 205 patients were treated for CRLM. In 134 pa-
tients a PH was performed and 29 patients were found
truly unresectable. In 42 patients local ablation with
CSA (n = 20, of which 7 in combination with PH) or
RFA (n = 22, of which 11 in combination with PH) was
performed. Baseline patient and tumor characteristics
were not different in the CSA, RFA, PH and truly
unresectable groups except for the number of metasta-
ses, CRS and surgical procedure (Table 1). In the RFA
and truly unresectable groups about 68% (35/47) of the
patients had more than one metastasis whereas in the
PH group 64% (86/134) of patients had a solitary metas-
tasis. Patients in the RFA group had a higher CRS as
compared to the other groups.
The indications for performing local ablation in the 42
patients were comorbidity precluding PH (n = 1, each
ablation group), bilobar disease with PH of one
hemiliver and unresectable liver tumors in the other
hemiliver (n = 6 CSA, n = 11 RFA), expected insufficient
future liver remnant (n = 10 CSA, n = 6 RFA) and in-
ability to perform a PH because of a unresectable deeply
located recurrence after previous hemihepatectomy (n = 1
CSA), localization in liver (n = 1 RFA), minimal residual
disease after chemotherapy (n = 2 CSA), or simultaneous
resection of colon in patients in whom a combination of
hemihepatectomy and primary tumor resection was con-
sidered not feasible (n = 3 RFA). In patients with solitary
liver metastasis (n = 14) ablation was in the majority
conducted because of an expected insufficient future liver
remnant. In a single case, the reason was the inability
to perform a PH because of a non-resectable deeply
located recurrence after previous hemihepatectomy, co-
morbidity precluding PH or minimal residual disease after
chemotherapy.
Complication rate
No postoperative mortality occurred after ablation. In
the PH group 6 out of 134 patients (4.5%) died within
30 days after surgery. Three postoperative deaths were
Table 1 Baseline patient and tumor characteristics
Clinicopathological characteristics CSA RFA PH Unresectable p-value
n 20 22 134 29
Median age (years) 66.7 60.0 62.3 60.8 0.151
(IQR) (9.3) (16.7) (13.8) (17.4)
Sex 0.392
Female 10 (50%) 10 (45%) 55 (41%) 8 (28%)
Male 10 (50%) 12 (55%) 79 (59%) 21(72%)
Site of primary tumor 0.732
Colon 12 (60%) 15 (68%) 84 (63%) 21(72%)
Rectum 8 (40%) 7 (32%) 50 (37%) 8 (28%)
Synchronous: metachronous liver metastasis 4:16 10:12 44:90 14:15 0.136
Interval resection of primary tumor and detection liver metastasis 0.385
≤12 months 9 (45%) 14 (64%) 88 (66%) 20 (69%)
>12 months 11(55%) 8 (36%) 46 (34%) 9 (31%)
Node status of primary tumor 0.479
Negative 8 (40%) 6 (27%) 50 (37%) 7 (24%)
Positive 12 (60%) 16 (63%) 84 (63%) 22 (76%)
Adjuvant chemotherapy after primary 0.470
No 12 (60%) 12 (55%) 92 (69%) 21 (72%)
Yes 8 (40%) 10 (45%) 42 (31%) 8 (28%)
Size largest metastasis (cm)
Median (IQR) 4.0 (2.0) 3.0 (2.0) 5.0 (4.5) 3.5 (4.0)* 0.440
Number of liver metastases <0.0001
1 10 (50%) 6 (27%) 86 (64%) 6 (21%)
>1 10 (50%) 16 (63%) 48 (36%) 19 (66%) γ
Preoperative CEA (μg/L)
Median (IQR) 21.2 (64.8) 12.0 (57.0) 22.5(71.4)$ 20.0 (116.3)& 0.623
CRS 0.009
≤2 15(75%) 10 (46%) 89 (66%)
>2 5 (25%) 12 (55%) 45 (34%)
Surgical procedure <0.0001
No resection 13 (65%) 11 (50%) - 29 (100%)
< Hemihepatectomy 6 (30%) 7 (32%) 36 (27%)
Hemihepatectomy 1 (5%) 3 (14%) 56 (42%)










CRS, Clinical risk score.
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monary complications. Complications occurred in 5/22
RFA patients (23%) and 10/20 CSA patients (50%,
p = 0.06). More severe complications like iceball cracks
(n = 2), biliary problems (n = 3) and kidney failure
(n = 2) were only present in CSA patients.Patterns of tumor recurrence and survival
In 106 of 176 patients (60%) recurrences developed
(Table 2). The rate of recurrences was higher in CSA pa-
tients (90%, 18/20) and RFA patients (73%, 16/22) than
in the PH group (54%, 72/134, p = 0.004). Recurrences
were at multiple sites in 12/20 CSA patients and in 3/22
RFA patients (p = 0.005). Ablation site recurrences were
seen in 9/20 CSA patients (45%) and in 4/16 RFA pa-
tients (18.2%, p = 0.096). In 7 of the 9 CSA treated pa-
tients with ablation site recurrences more disseminated
recurrent disease was present. In RFA treated patients
only 1 out of 4 ablation site recurrences was part of
more disseminated recurrences. In 5/16 RFA treated
patients with recurrences a liver directed second proced-
ure could be performed because the recurrences were
confined to the liver (ablation site: n = 2, liver remnant:
n = 2, or both: n = 1). In the CSA group 3/18 patients
with recurrences underwent a reoperation; two because
of an ablation site recurrence and one because of a re-
currence in the liver remnant.Table 2 Patterns of recurrence and survival after
cryosurgical ablation (CSA), radiofrequency ablation
(RFA) or partial hepatectomy (PH) of colorectal liver
metastases
CSA RFA PH
(n = 20) (n = 22) (n = 134)
No recurrences 2 6 62
Recurrences 18 16 72
Single site 6 13 45
Abdomen (extrahepatic) 1 4 8
Liver remnant 2 5 12
Ablation site 2 3
Lung/thorax 1 1 20
Other single sites - - 5
Multiple sites 12 3 27
Ablation site recurrences 9 4
- ablation site only 2 3
- ablation site and other sites 7 1
Median interval to recurrence (months) 8.5 9.0 9.0
(Range) (3–44) (2–31) (3–72)
Median overall survival (months) 17.6 51.7 43.4
5-year overall survival rate (%) 5 38 42Overall actual survival for the CSA, RFA, PH and truly
unresectable group are shown in Figure 1. The median
survival of patients treated with RFA (51.7 months) or
PH (43.4 months) was longer (p < 0.0001) than the
median survival of both the CSA treated group
(17.6 months) and the truly unresectable group
(19.9 months). Results of multivariate analysis using Cox
regression, showing the relative risk of dying (overall
survival) and relative risk of recurrence (disease-free sur-
vival) and 95% confidence interval (CI) compared to the
reference standard partial hepatectomy (PH, 1.00) are
shown in Table 3.
On multivariate analysis the type of surgical procedure
and the clinical risk score were independent prognostic
variables both for overall survival and disease-free sur-
vival. Of note, on multivariate analysis, the relative risk
of dying or developing recurrent disease after RFA was
not different (RR: 0.84; 95% CI: 0.50-1.45, p > 0.50) as
compared to the reference group of patients after PH.
Response in the subset of patients treated with ablation
alone
Baseline patient and tumor characteristics
A comparison of the patients solely treated with open
ablation revealed no differences in age (median (IQR):
CSA 70 (9.4), RFA 60 years (22.7)), size of treated metas-
tasis (median (IQR): CSA 4.5 (3.0) cm, RFA 5.5 (4.3)
cm), number of metastases 1:>1 (CSA 4:2, RFA 2:4), me-
dian (IQR) CRS (CSA 1.5 (1.5), RFA 2.5 (1.3)), orFigure 1 Kaplan-Meier survival plot of overall survival in
patients with colorectal liver metastases according to
treatment. Partial hepatectomy includes patients treated only by
partial hepatectomy. Thermoablation includes patients treated with
thermoablation with or without partial hepatectomy.
Table 3 The relative risk of dying, recurrence and 95% confidence interval compared to the partial hepatectomy
Prognostic factor Risk of dying Risk of recurrence
Relative risk 95% CI P Relative risk 95% CI P
Surgical procedure <0.0001 <0.0001
PH 1.00 1.00
Truly unresectable 2.63 1.43-4.82 0.002 2.63 1.43-4.82 0.002
CSA 3.27 1.99-5.37 <0.0001 3.12 1.91-5.11 <0.0001
RFA 0.84 0.49-1.45 0.54 0.84 0.50-1.43 0.52
Clinical risk score 0.002 0.002
0 1.00 1.00
1 3.14 0.96-10.3 0.059 2.50 0.88-7.09 0.085
2 2.72 0.84-8.84 0.097 2.26 0.81-6.33 0.12
3 4.81 1.47-15.78 0.01 3.81 1.34-10.80 0.012
4 6.66 1.94-22.92 0.003 5.53 1.86-16.49 0.002
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(152.5) minutes), all p >0.05.
Proteomics analyses of serum response after CSA versus
RFA
As shown in Figure 2A, ablation induced a biphasic pat-
tern with more than 70 changes in protein abundance in
serum at time point 0 (Figure 2 panel A). At this time
point as well as all subsequent time points more changes
were observed with CSA than with RFA as is also evi-
dent from the AUC (Figure 2 panel B). At time points 1,
2 and 4 the largest differences were found (Figure 2
panel C).
Biochemical and angiogenic growth factor serum response
after CSA versus RFA
Baseline values at day −1 of biochemical and angiogenic
growth factors were not different in the RFA versus the
CSA group (data not shown). The total response of
serum CRP, albumin, LDH, ALAT, thrombocyte count
and AT II was not different except for LDH which was
higher in the CSA group versus the RFA group
(p = 0.02, data no shown). The median (IQR) baseline
values for VEGF were 270.0 (308.9) pg/mL, HGF:
1,529.0 (872.4) pg/mL, Ang-1: 27,719.5 (22,635) pg/mL,
Ang-2: 1,988.3 (1,107.0) pg/mL, endostatin: 136.1 (47.8)
ng/mL, Angiostatin: 53.1 (73.0) ng/mL, and for Tie-2:
28.0 (12.0) ng/mL. The percentual change of the serum
levels of the various angiogenic factors is presented in
Figure 3. All molecules playing a role in the pro-
angiogenic response (VEGF, Tie-2, Ang-2 and HGF)demonstrate an increase in serum levels after ablation.
Ang-2 and HGF show an immediate postoperative in-
crease whereas VEGF serum levels start to rise only after
day 1. Tie-2 levels demonstrate an initial decline before
they start rising above baseline levels after day 1. The ra-
tio Ang-2/Ang-1 increases sharply after operation with
an increase to >400% at day 1 after operation, which
stays high the second day for RFA. The vessel stabilizing
factor Ang-1 shows a decline after ablation. The inhibi-
tors of angiogenesis, endostatin and angiostatin show a
slightly different response. Endostatin levels reveal a
postoperative decline with restoration to baseline levels
at day 4. Angiostatin levels demonstrate a 40% increase
at the end of the operation with a decline afterwards. A
comparison of the AUC for the angiogenic molecules
did not reveal differences (p >0.310) between CSA
versus RFA.
Discussion
For patients with unresectable CRLM thermoablation is
a potential curative option, and both RFA and CSA are
applied [26,27]. The aim of the present study was to
compare the clinical outcome in patients with CRLM
treated with CSA versus those treated with RFA and to
more specifically analyze temporal changes in serum
proteome expression as well as molecules relevant for
the pro-angiogenic and anti-angiogenic balance in pa-
tients treated with CSA or RFA.
We found that CSA does not contribute to prolonged
survival because the median overall survival of patients
treated with CSA is as poor as truly unresectable
Figure 2 SELDI-TOF-MS proteomics time series analyses. Proteomics analyses of differences in serum protein abundance in samples obtained
from six patients treated with radiofrequency ablation (RFA: ♦) and six patients treated with cryosurgical ablation (CSA: ■). Panel A: number of
differences for RFA and CSA compared to time point −1 (before surgery). Panel B: AUC is higher at time points 1 through 4 for CSA than for RFA.
Panel C: number of differences between RFA and CSA. Time −1 = day of admission; 0 = at the end of operation; 1–4 = postoperative days 1–4.
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tients treated with RFA (51.7 months) is comparable to
that of patients treated by PH (43.4 months). Remark-
ably, this comparable survival is despite a negative selec-
tion of RFA patients, as reflected by a higher clinical risk
score as compared to PH patients. We also found that
recurrences after CSA are more often at multiple sites as
compared to recurrences after RFA, which are more
often at single -and thus potentially surgically treatable-
sites. A possible explanation for this is that CSA has
more profound systemic effects than RFA, which, if it is
associated with a sepsis-like condition, is known as the
“cryoshock phenomenon”. Our proteomics analyses of
serum protein dynamics indeed showed a biphasic pat-
tern with consistently more changes in serum protein
abundance with CSA compared to RFA at all-time
points measured. This biphasic pattern is similar to that
observed in a previous study [25] on the kinetics of the
serum proteome after colon surgery and reminiscent of
an acute phase response that appears more severe with
CSA than with RFA.
This indicates that the response to CSA is more ag-
gravated and thereby creates an environment in which
circulating tumor cells are more likely to adhere toactivated endothelial cells in remote organs and tissues
and thus contribute to tumor seeding of micrometas-
tases. Also in rodents an augmented systemic inflamma-
tory response has been demonstrated after CSA [15,28].
Based on the proteomics results, we subsequently tried
to identify whether angiogenic proteins are part of this
protein abundance after CSA. These angiogenic proteins
could probably initiate the angiogenic switch resulting in
progression of non-angiogenic micrometastases into
clinically detectable tumor masses [29,30]. Therefore we
hypothesized that CSA is associated with a more pro-
nounced pro-angiogenic serum response than RFA.
Based on an exploratory analysis of pro-angiogenic and anti-
angiogenic molecules we conclude that thermoablation of
CRLM is associated with a pro-angiogenic response, but that
the angiogenic serum response was comparable in CSA and
RFA patients; the time course analysis after thermoablation
of all investigated angiogenic molecules revealed no statisti-
cally significant differences. Current knowledge with respect
to angiogenesis states that Ang-1, which is widely expressed
in human tissues, constitutively activates Tie-2, which is
almost exclusively expressed in endothelial cells, and there-
by maintains blood vessel [21,31]. Ang-2 is mainly produced
by endothelial cells and is active at sites of vascular remo-
Figure 3 Percentual change in angiogenic factors in patients treated with open ablation (CSA versus RFA ). Panel A: VEGF, B: Tie-2,
C: HGF, D: endostatin, E: Ang-1, F: Ang-2, G: Ratio Ang-2: Ang-1, H: Angiostatin. Thermoablation is associated with a pro-angiogenic response as
reflected by an increase in serum levels of pro-angiogenic molecules (VEGF, Tie-2, Ang-2 and HGF). The response is comparable in patients with
CSA and RFA treated tumors. Baseline values at time point −1 are set at 100%. Time −1 = day of admission; 0 = at the end of operation;
1–4 = postoperative days 1–4.
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Upregulation of Ang-2 results in binding to Tie-2 and
destabilization of vessels, which in the presence of pro-
angiogenic cytokines, like VEGF, will result in angiogenesis,
whereas in the absence of pro-angiogenic activity vessel re-
gression will follow. Especially relevant in this respect is the
Ang-2/Ang-1 ratio, which is often increased in tumors and
its surroundings, which suggests that the angiogenic balance
is tipped towards a pro-angiogenic state [32-34]. Also in the
present study we found a four-fold increase in the Ang-2/
Ang-1 ratio at day 1 and a slow decrease afterwards but still
a two to three-fold higher ratio at day 4 after the ablation.
Interestingly, Ang-2 also potentiates the effect of inflamma-
tory cytokines by induction of expression of several adhesion
molecules [35]. This tight relation between the inflammatory
response and Ang-2 serum levels is exemplified in our study
by the similar course of Ang-2 serum levels and CRP levels,
both of which have their peak values at day 2 after ablation.
It is of interest to evaluate whether the magnitude of the
procedure is of influence on the levels of these growth fac-
tors. In one study in patients after partial hepatectomy sub-
stantially higher HGF and VEGF serum levels were found as
compared to our data, suggesting a correlation between the
extent of the procedure [36].
Median survival and overall 5-year survival after RFA
and PH are comparable to those in a recently published
large series of predominantly resected patients [37].
What is the evidence that thermodestruction by heat
(RFA) has different pathophysiological effects as com-
pared to ablation by cold (cryoablation)? The mecha-
nisms through which cryoablation induces cell injury
have recently been reviewed [38]. Gage et al. nicely sum-
marizes literature evaluating the lowest temperature
which should be reached to induce tissue damage –the
lethal temperature-; it shows that this is highly variable
in various tissues and organs. One of the most potent ef-
fects of thermoablation is derangement of protein stabil-
ity. Remarkably, these effects have been less intensely
studied during freezing as compared to during heating
[39]. In a study in mice subjected to cold stress it was
demonstrated that induction of heat shock proteins
–responsible for protection of cells to stress- is different
in hypothermia versus hyperthermia [40]. Also, in a rat
model of ventilator-induced lung injury, plasma levels of
pro-inflammatory cytokines were highest in hyperther-
mic rats as compared to hypothermic rats; the reverse
holds true for the anti-inflammatory interleukin-10 [41].
In vitro experiments using human white blood cells
stimulated by lipopolysaccharide at various temperatures
revealed a temperature dependent dysregulation of sev-
eral microRNAs regulating cytokine production [42].
The differences between the responses to hyperthermia
versus hypothermia were very nicely demonstrated in a
study using microarray analysis of gene expression in ahuman hepatocellular carcinoma cell line [43]. The
authors were able to demonstrate that hypothermia in-
duces changes in relative expression of 409 gene expres-
sion sequences, whereas hyperthermia induces changes
in “only” 71 sequences. Burattini et al. [44] reviewed the
response patterns of cells under the influence of various
physical agents. They summarized that mild heat expos-
ure of cell cultures mainly induces cell apoptosis which
is in contrast to hypothermia which rarely induces apop-
tosis but more frequently necrosis. All these data suggest
that the pathophysiological response to thermoinjury is
variable and dependent on the temperature changes. Of
note, the above mentioned papers all study temperature
changes in the physiological range whereas cryoablation
or radiofrequency ablation creates temperatures in the
supranormal or subnormal range of temperatures. Fur-
ther evaluation of the response to RFA or cryoablation
in humans with liver tumors is warranted to more
clearly elucidate the pathophysiological responses in re-
lation to dissemination and growth of tumor cells.
A possible limitation of our study could be that the
fast development of the ablation equipment has resulted
in more effective ablation devices nowadays. However,
we think that it is the low temperature which destroys
the tumor and additionally an adequate margin around
the tumor dictates the success of the treatment. As long
as these two prerequisites are fulfilled the type of device
which creates the ice ball is, to our opinion, less of im-
portance. Another limitation of the study is the small
number of patients in whom the analysis of proteomic
dynamics and angiogenic molecules was performed. The
patients in both groups were however highly comparable
with respect to baseline characteristics, treatment (solely
by ablation), transfusion requirements (none) and post-
operative complications (none). All of these can influ-
ence the results of serum protein profiles and angiogenic
molecules. Another strong aspect of this study is that it
is the first which investigates a set of angiogenic markers
instead of just one relevant angiogenic factor, for in-
stance VEGF, as is often done in the literature. Using this
approach we were able to measure an integral response
of key molecules relevant in the balance of pro-
angiogenesis and anti-angiogenesis. Despite these li-
mitations our study has advantages in that it is a
monocentric study and patients were treated in a
protocolled manner. Another important advantage of
the present study is the strict and closed follow-up with
none of the 205 patients lost to follow-up for other rea-
sons than death. Moreover, because all patients were in-
cluded before May 2006 they all had a potential minimal
follow-up of 5 years. Therefore the survival analysis of
all patients is based on actual data instead of estimations
which form the basis for actuarial survival. Censored pa-
tients (those with missing information on survival time)
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survival [45,46].
Conclusions
We have shown that in patients with unresectable
CRLM, RFA significantly improves survival, even up to
the same survival as is obtained with PH. In contrast,
CSA does not contribute to a better survival and is asso-
ciated with a higher complication rate. Although –based
on the proteome analysis- we found that CSA initiates a
more profound response we could not find a difference
in biochemical or angiogenic response. Ablation gener-
ates changes in circulating angiogenic factors favoring a
pro-angiogenic environment. Further studies are needed
to examine which proteins are contributing to the more
pronounced effect on protein kinetics in CSA treated
patients.
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